Skip to content

Clinical study of acupuncture and moxibustion treatment for Cohn's disease

Molecular regulation mechanism of acupuncture and moxibustion therapy in inhibiting epithelial-mesenchymal transition of intestinal fibrosis in Crohn's disease

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-16007751
Enrollment
Unknown
Registered
2016-01-13
Start date
2016-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

Acupuncture Group:Acupuncture, Moxibustion, Prednisone and azathioprine
Placebo acupuncture group:Placebo acupuncture, moxibustion, Prednisone and azathioprine
Drug Group:Prednisone and azathioprine

Sponsors

Shanghai Research Institute of Acupuncture and Meridian
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) in accordance with the criteria for diagnosis of Crohn's disease; (2) mild or moderate disease activity index (CDAI) in patients with chronic active stage between 151 and 450; (3) syndrome or deficiency of spleen and kidney yang deficiency of spleen and stomach and qi stagnation and blood stasis; (4) age 16-70 years old, the gender is not limited; (5) patients who did not take any medication for CD symptoms, or only those with salicylic acid; (6) no prior hormone therapy or received hormone therapy (prednisone is less than or equal to 0.5mg/kg/day), over the past three months without the use of immunosuppressive agents or biologic agents; (7) voluntarily participated in this trial and signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) pregnancy, pregnancy or lactation; (2) at the same time with heart, brain, liver, kidney and hematopoietic system of serious diseases; (3) patients with a simultaneous psychiatric or other severe disease; (4) in this study selected point regions are skin diseases, fistula, fistula and mutilated and to perform acupuncture treatment; (5) drug users who may lead to exacerbation of CD symptoms or affect the efficacy of the treatment method in this study because of other diseases; (6) patients with short bowel syndrome, symptoms of intestinal stenosis, who had received abdominal or gastrointestinal surgery in the past six months.

Design outcomes

Primary

MeasureTime frame
Crohn's disease activity index;SES-CD;

Secondary

MeasureTime frame
Inflammatory bowel disease quesionnaire;Hospital Anxiety and depression scale;CRP, ESR and PLT;

Countries

China

Contacts

Public ContactYin Shi
flysy0636@163.com+86 021 64383910

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026